- Home
- GFS vs BIIB Comparison
GFS vs BIIB Comparison
Compare GFS & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GFS
- BIIB
- Stock Information
- Founded
- GFS 2009
- BIIB 1978
- Country
- GFS United States
- BIIB United States
- Employees
- GFS N/A
- BIIB N/A
- Industry
- GFS Semiconductors
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- GFS Technology
- BIIB Health Care
- Exchange
- GFS Nasdaq
- BIIB Nasdaq
- Market Cap
- GFS 22.4B
- BIIB 20.6B
- IPO Year
- GFS 2021
- BIIB 1991
- Fundamental
- Price
- GFS $42.43
- BIIB $140.60
- Analyst Decision
- GFS Buy
- BIIB Buy
- Analyst Count
- GFS 15
- BIIB 27
- Target Price
- GFS $50.47
- BIIB $220.50
- AVG Volume (30 Days)
- GFS 2.8M
- BIIB 1.6M
- Earning Date
- GFS 02-11-2025
- BIIB 02-12-2025
- Dividend Yield
- GFS N/A
- BIIB N/A
- EPS Growth
- GFS N/A
- BIIB 40.28
- EPS
- GFS N/A
- BIIB 11.18
- Revenue
- GFS $6,750,000,000.00
- BIIB $9,675,900,000.00
- Revenue This Year
- GFS $5.27
- BIIB N/A
- Revenue Next Year
- GFS $11.48
- BIIB N/A
- P/E Ratio
- GFS N/A
- BIIB $12.58
- Revenue Growth
- GFS N/A
- BIIB N/A
- 52 Week Low
- GFS $35.85
- BIIB $128.51
- 52 Week High
- GFS $61.98
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- GFS 50.56
- BIIB 44.88
- Support Level
- GFS $36.27
- BIIB $135.02
- Resistance Level
- GFS $47.69
- BIIB $141.69
- Average True Range (ATR)
- GFS 2.19
- BIIB 4.00
- MACD
- GFS 0.46
- BIIB 0.04
- Stochastic Oscillator
- GFS 53.94
- BIIB 59.44
About GFS GlobalFoundries Inc.
GlobalFoundries is a top-five contract semiconductor manufacturer globally. It was originally the manufacturing arm of Advanced Micro Devices before it was spun out in 2009. The foundry sells chips into a range of end markets including smartphones, PCs, Internet of Things, data centers, automotive, industrial, and so on, but primarily focuses on more mature process technologies. Until 2021, the firm was privately held by Mubadala Investment, the sovereign wealth fund of the United Arab Emirates. GlobalFoundries merged with Chartered Semiconductor Manufacturing in 2009 and acquired IBM's chipmaking business in 2015. GF is headquartered in Malta, New York, and employs about 12,000 people.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.